Stock Analiz

Bioharvest Sciences Inc. BHST

· data as of November 13, 2026

$1.50Market cap $34M
Open the interactive analysis →

Bioharvest Sciences Inc. (BHST) is a company listed in the US with a market value of about $34M. In the twelve months to September 30, 2026 it had revenue of $34M and net income of -$12M, a net margin of -34.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -78%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 3% below the current price.

About Bioharvest Sciences

Bioharvest Sciences is listed in the US. It was profitable in 0 of the last 3 years in our data.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.0
P/B1.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-28.1%
Shareholder yield0.0%
Intrinsic value vs. price−3%

Growth and quality

Revenue growth (1 yr)37.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-60.9%
ROIC (5-yr avg.)-77.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal yearTTM202520242023
Revenue$34M$35M$25M$13M
Net income-$12M-$11M-$13M-$13M
Free cash flow—-$10M-$10M-$10M
EPS (diluted)$-0.56$-0.49$-0.57$-0.55
Net margin-34.7%-32.3%-51.3%-99.2%
ROIC—-21.6%-133.4%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $9.25, 515% above the current price; targets range from $5.00 to $14.00; the consensus rating is “Strong buy”; expected EPS is $-0.55 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Bioharvest Sciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 3% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Bioharvest Sciences pay a dividend?

Not currently.

Is Bioharvest Sciences a good stock to buy?

We do not give buy or sell advice. Bioharvest Sciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.